Cervical cancer is caused by approximately 15 highrisk types of the human papilloma virus (HPV), notably types 16 and 18, which together give rise to around 70% of all cases. Although infection of the cervix with HPV is very com mon, there would be no (or virtually no) cervical cancer without HPV infection [6] . In most cases, the body's immune system clears a cervical HPV infection within a year or two [7] . Highrisk HPV (hrHPV) infection may lead to highgrade CIN, which sometimes progresses to cervical cancer. The time it takes for an hrHPV infection to develop into cervical cancer varies hugely, but it is very rare for cancer to develop in less than 7 years and it is not uncommon for cancer to develop more than 30 years after infection.
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HPV testing
Since hrHPV infection is needed for cancer to develop and because hrHPV DNA is still pres ent during the development of cancer, looking for hrHPV DNA should be a good approach for identifying women with highgrade CIN. In addition, as the time from hrHPV infection to cancer is long, a woman who is HPVnegative is extremely unlikely to develop cervical cancer over the next 5-10 years and infrequent screening would be safe. Therefore, there are two potential uses for HPV testing: to identify those likely to have disease now (and would benefit from treat ment); and to identify those who might develop disease in the next few years (or by elimination of those who are extremely unlikely to develop dis ease over the next several years, and therefore do not need to be screened again for several years). However, any HPV assay used for screening purposes will need to be clinically validated for the detection of CIN2+. Most commercial HPV Cervical screening works by detecting and treat ing highgrade cervical intraepithelial neoplasia (CIN), typically CIN2 and above (CIN2+), or in some settings CIN3 and above (CIN3+). In the absence of treatment some, but not all, CIN3 would progress to cervical cancer [1, 2] . Cer vical cancer is rare in women previously treated adequately for CIN [3, 4] .
For many years cervical screening was carried out by conventional cytology; a sample was col lected using a spatula and smeared onto a glass slide before being analyzed under a microscope in a laboratory. Today many screening programs use liquidbased cytology instead; samples are now collected using a small plastic broom and stored in a liquid transport medium. Glass slides are pre pared from the cells in this transport medium in the laboratory. Liquidbased cytology is consid ered to be better than conventional cytology, in that it is easier and quicker to see what is on the slide, but research studies have not shown that it is better than conventional cytology at detecting highgrade CIN [5] .
The success of effective screening programs stem from their good coverage (e.g., in the UK approximately 80% of the target population has been screened in the last 5 years) and the highlevel of quality assurance. Cervical cytology depends on the collection of good samples and the skilled interpretation of cells under the microscope. Both activities require extensive training and continu ous quality assurance. Examining cells under a microscope is a skilled job that relies on concentra tion (so as not to miss something of significance) and human judgment to interpret what is seen. Cervical screening has been ineffective in most lowresource countries because of an inability to obtain high coverage with a reliable screening test.
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Human papillomavirus testing has been shown to be far more sensitive and robust in detecting cervical intraepithelial neoplasia 2 and above (and cervical intraepithelial neoplasia 3 and above) for cervical screening than approaches based on either cytology or visual inspection; however, there are a number of issues that need to be overcome if it is to substantially reduce the morbidity and mortality associated with cervical cancer at the population level. The two main issues are coverage (increasing the number of women who participate in screening) and the management of women who test positive for high-risk human papillomavirus. This article will review the potential for vaginal self-collection to improve coverage and the options for triage of high-risk human papillomavirus-positive women in high-resource and low-resource settings.
tests are based on DNA, but two are based on RNA. One of these tests is restricted to five HPV types and has lower sensitivity, and the other has similar sensitivity to the DNAbased test [8] .
There have been many studies comparing HPV testing to cytology for the detection of highgrade CIN. All large studies have found that HPV testing is at least as good as cytology at detecting highgrade CIN and most studies find HPV testing to be better (i.e., it is more sensitive) [9] [10] [11] [12] . The disadvantage of HPV test ing is that it is less specific than cytology. That is, among women without highgrade CIN more will test positive for HPV than will have abnormal cytology.
Another advantage of HPV testing is that it does not depend on the preservation of good quality morphology. In stark contrast to cyto logy, reasonable results can be obtained by using HPV testing on samples that women collect themselves [13] . Furthermore, HPV testing does not rely on human judgment and the results are reproducible in different laboratories. In studies comparing cytology to HPV testing in Europe and North America [11] , the sensitivity of cyto logy varied from less than 40% to approximately 80% (average 53%), whereas the sensitivity of clinicianbased HPV testing was consistently above 85% (average 96%). The specificity of both tests increased with age; however, cyto logy was on average more specific (96%) than HPV testing (91%).
Longitudinal studies show that the rate of highgrade CIN after a negative HPV test is considerably less than the rate after negative cytology [14] [15] [16] [17] . In a joint European study, the cumulative risk of CIN3+ 6 years after a negative HPV test was significantly less (0.27%) than the cumulative risk 3 years after a negative cytology (0.51%) [14] . One study of cervical cancer inci dence in the 5 years following screening with both cytology and HPV testing reported half the rate of cervical cancer following a negative HPV test compared with following a negative cytology test [18] .
Randomized controlled trials (RCTs) have shown that the additional cases of highgrade CIN, picked up by HPV testing but missed by cytology, are not simply indolent diseases that would not have progressed to cancer in the short term. In all four RCTs of cytology versus HPV testing within established screening programs with published results for the second round of screening, the rate of highgrade CIN detected at round two (i.e., between 1 and 5 years after enrolment) was substantially lower (~half) in those individuals originally screened by HPV testing compared with those originally tested by cytology alone [19] [20] [21] [22] . Thus, by treating more women in the first round, the trials found that there was less detected in the second round. Fur thermore, the limited data on the incidence of cervical cancer in RCTs suggest that HPV testing does indeed result in fewer cases of cervical can cer on followup. In the Italian trial, there were nine cancers in the cytology arm compared with none in the HPV arm after the initial screen [22] and in the Dutch trial there were 14 versus four [21] . Results in the Swedish trial including those detected at first screen, found five squamous cell carcinomas in the cytology arm and one in the HPV arm [20] .
Initially, many people believed that HPV testing was too expensive to be used in middle and lowincome countries, and that cytology or simply looking at the cervix would be adequate to greatly reduce the burden of cervical cancer. There was much interest in visual inspection after the application of dilute acetic acid (VIA). Indeed, for many years VIA was the favored approach of the Alliance for Cervical Cancer Pre vention; one of the main organizations working to prevent cervical cancer in developing coun tries. However, a trial in the San Martin region of Peru that compared conventional cytology, VIA and HPV testing to screen over 5000 women found that the sensitivity of HPV testing was far superior to that of cytology and VIA, and that the specificity of VIA was considerably lower [23] . Furthermore, a cluster randomized trial in India, reported "34 deaths from cervical cancer in the HPVtesting group, compared with 64 in the control group (hazard ratio: 0.52; 95% CI: 0.33-0.83). No significant reductions in the numbers of advanced cancers or deaths were observed in either the cytology group or the VIA group, as compared with the control group" [24] .
Management of women positive for HPV
The great advantage of HPV testing for most women is that HPVnegative women can have their screening interval extended to over 3 years [14] . By extending the screening interval to 6 or even 10 years, the proportion of women who will test positive on at least one HPV screen by the age of 65 years will be similar to the proportion who test positive on at least one cytology screen in current programs. Since the rate of disease fol lowing an abnormal HPV test is half the rate of disease following an abnormal cytology, where the screening interval is 5 years, extending the screening interval to 10 years should roughly result in the same number of women testing positive as they currently do.
The greater proportion of women testing HPV positive on a single screen (compared with the proportion with abnormal cytology) need not be a problem as demonstrated by the very large trials of primary HPV testing that have been run suc cessfully in several countries (including England) [19] . The first solution is good management of HPVpositive women. A positive HPV test in pri mary screening should only trigger a triage test, not automatic referral to colposcopy. The most widely studied triage test in this situation is cytol ogy. Triage with cytology can be carried out on the same sample as the HPV test without the need for women to attend another clinic visit (when the sample is taken using liquidbased cytology transport medium). Effectively, the same women (those positive on both cytology and HPV test ing) are immediately referred to colpo scopy regardless of whether one screens using cytology, triaged by HPV testing, or HPV testing, triaged by cytology [25] . In practice, because cytology is subjective, more women may be considered mor phologically abnormal when they are known to be HPVpositive. Evidence of this was observed in the Finnish trial, where women were referred to colposcopy based on their cytology result, in particular women under the age of 35 years [12] . Introduction of primary HPV testing should be closely monitored to assess whether the increase in morphologically abnormal cytology is associated with the learning curve or whether it will affect referral rates in the long term. Conversely, a very small number of women who would be referred to colposcopy with highgrade cytology, without HPV triage, will test negative for HPV and will not have cytology triage. HPVpositive women with normal cytology will be rescreened at a shorter interval (e.g., every 12 months). In this way, the sensitivity of HPV testing will be main tained, but the numbers referred for colposcopy need not be excessively increased.
Current proposed strategies to deal with HPVpositive/cytologynegative women sug gest they should be retested 12-24 months later (with HPV and cytology). Women who are still HPVpositive or those who develop cytological abnormalities upon retesting are referred to colposcopy [26] [27] [28] . Support for this strategy comes from cohort study evidence that suggests that 90% of HPV infections will be selfclearing in a period of 1-2 years [15, 16] . Nevertheless, referring all women who test HPVpositive/cytologynegative twice, 12 months apart, leads to higher colposcopy referral rates than those observed in cytology screening programs.
Genotyping for HPV16 & HPV18
Genotyping for HPV16 and HPV18 has been proposed as a good alternative for women who test HPVpositive/cytologynegative because the risk of CIN3+ is genotypedependent [25, 29, 30] and HPV types 16 or 18 are found in over 70% of cervical cancer [31] . HPV16 (but not HPV18) is associated with a high crosssectional rate of CIN2+ and CIN3+ [8] . Women with HPV18 and HPV45 are more likely to develop cervical intraepithelial neoplasia (particularly adenocar cinomas in the endocervical canal) than women with other highrisk types [31, 32] . The risk of CIN3 reaches 10% over 1-4 years for HPV16 positivity and over 2-5 years for HPV18 posi tivity [30, 33] . By contrast, the 12month risk of CIN3+ after a HPVpositive/cytologynegative test ranges from 0.8 to 4.1% [26] .
Studies have shown that HPV DNA testing followed by triage with cytology and screen ing for persistent HPV typespecific infection (genotyping) has a considerably higher sensi tivity for detecting CIN3+ than screening by cytology alone, with a modest increase in screen ing tests and referrals [25, 28] . These results have been validated as part of the ATHENA trial in a scenario where HPV was the primary test [9] . Being hrHPVpositive but HPV16/18negative, carries an increased risk of CIN3 in the follow ing 2 years of 2.9% [21] . For this reason, the lack of HPV16/18 cannot be used to return women to routine screening.
Genotyping for triage has been primarily investigated in women over the age of 30 years. In younger women, the proportion testing HPV16/18 positive may be too high to justify referring them all; however, the proportion of CIN3+ harboring HPV16 also decreases in older women, indicating the need for careful followup of hrHPV women regardless of HPV type [9] .
Immunocytochemical detection of p16INK4a
Triage using other biomarkers has been less com prehensively evaluated. One particularly promis ing test is the immunocytochemical detection of overexpression of the p16INK4a tumor suppres sor gene as a surrogate marker for the transform ing activity of hrHPV oncoproteins, which are essential for the initiation and maintenance of the neoplastic process. A number of studies look ing at p16INK4a staining of cervical cytology showed that women with CIN1 who are positive for p16 were more likely to be subsequently diag nosed with CIN2+ [34] [35] [36] . Unfortunately, the sensitivity of p16 varies hugely in the literature owing to difficulties in reading the slides, lack of standardized reporting and a need for substan tial expert interpretation. In general, p16 is less sensitive for CIN2+ or CIN3+ than HPV test ing, but most studies have found it to be more specific at identifying women with highgrade disease [8, [37] [38] [39] .
A more recent development has been double staining for p16INK4a and Ki67. Several stud ies investigating the performance of the paired markers p16INK4a/Ki67 found that the results were quite similar to p16INK4a alone. The main difference between the single and the paired markers is that p16INK4a should be read by an expert and requires considerable interpretative skills to rule out false positives due to staining of endocervical and other cells. By contrast, the p16INK4a/Ki67 marker pair is read differently and can be more easily interpreted correctly by a less experienced cytopathologist [38, [40] [41] [42] . A study by Carozzi et al. is of particular interest since good results for p16INK4a were demon strated in women aged 25-34 years, showing that p16INK4a may be considered as a triage marker for these hrHPVpositive women [38] . A recent paper from the same study with additional followup showed that p16INK4a positivity in hrHPVpositive women had a cumulative 3year absolute risk for CIN2+ of 19.5% with a longi tudinal sensitivity of 75.6% [43] . The data sug gest that p16INK4a may be considered as an option for triage of hrHPVpositive women.
DNA methylation
DNA methylation (DNAme) of hostcell DNA has been proposed as an alternative triage for hrHPVpositive women because DNAme plays an essential role in gene transcription and genomic stability. Aberrant methylation leads to cell immortality and malignant transformation [44] . The use of DNAme for triage would have the advantage of being an automated, objective test that could be run on the same sample as the HPV assay.
Of the more than 50 human genes tested so far in cervical tissue, 15 have been reported in five or more studies and three genes (CADM1, DAPK1 and RARB) have been repeatedly shown to have elevated methylation in cervical cancers [45] . Hesselink et al. evaluated CAD1/MAL methylation to triage HPVpositive women in a large populationbased screening study [46] .
They found it to be as effective at detecting CIN3+ in HPVpositive women as cytology with HPV16/18 genotyping. Studies of host cell methylation use different clinical specimens, methylation assays, assay thresholds and/or selected promoter regions, making consistency among results difficult [44] .
The methylation of HPV genes, especially HPV16, in disease progression has been a major focus of research. Elevated methylation of the HPV16 L1 and L2 open reading frames in par ticular is associated with highgrade CIN and invasive cancer [47] [48] [49] . Recently the association between specific patterns of DNAme in HPV16 L1 and L2 and highgrade CIN has been vali dated in a small prospective study [50] . Further validation in larger studies is required. The potential utility of methylation of other regions of the HPV16 genome as a biomarker for CIN2+ is less clear because studies have been small and the results highly variable. To expand the poten tial utility of HPV16 methylation assays for pre dicting the risk of cancer additional research needs to be directed to other HPV types, such as 18, 31, 33 and 45.
DNAme of a panel of both human and HPV gene markers is an exciting area of current research.
Vaginal self-collection for HPV testing
For years conventional cervical screening has relied on cliniciancollected cervical specimens; however, vaginal selfcollection for HPV testing is likely to become an integral part of screening in both the developed and developing world. This is because selfcollection has the potential to overcome two major problems inherent in current screening strategies: cost and coverage. It is difficult to maintain the large numbers of clinics required for mass population screening, especially in resourceconstrained regions. Even in countries that manage to do this well, compli ance of 80% with the recommended screening intervals is considered extremely good. Women who are not screened or attend infrequently are at the highest risk of developing cervical cancer [51] . Studies have shown that selfcollection for HPV testing is a practical and effective way to collect exfoliated cell specimens from the vagi nal tract and cervix that is broadly acceptable to women and eliminates the cost of visiting a clinician [52] [53] [54] [55] .
Acceptability of vaginal self-collection
Numerous studies in a wide variety of countries and ethnic groups over the past decade have perspective -Lorincz, Castanon, Lim & Sasieni reported that selfcollection is well accepted by women and in some more educated groups may be preferred to speculumbased cervical sampling [56] [57] [58] [59] [60] [61] . Virtually all measures of acceptability, including pain, embarrassment and anxiety favor the selfcollection approach. However, a consistent negative theme across the studies is that 50-70% of women worry they will not take the sample properly [56] [57] [58] 62] . This is actually a misconception, it is easy for a woman to take a selfcollected sample correctly and the samples are almost always good. There do not appear to be any specific cultural or religious barriers to selfsampling [62, 63] , although one study in the UK found that Muslim women were reluctant to use the selfcollection approach [52] .
The main problem in highincome countries with wellestablished screening programs is low coverage and falling participation rates. A well recognized barrier to cervical screening atten dance is the need to undergo a pelvic examina tion, which some women find to be uncomfort able, invasive or unacceptable (for emotional or cultural reasons) [54] . However, practical barriers may be more predictive of nonattendance behav ior [64] . The selfcollection approach allows the women to obtain samples in privacy and com fort, with the additional benefit of being able to choose the time and place of sampling.
The devices most commonly used for self collection are swabs, which may be made of spun polyester fiber or treated cotton on a plastic shaft or special flocked swabs with a somewhat rough surface; untreated cotton swabs should not be used. Another device is a small soft nylon brush similar in shape to an artist's brush, but with much wider diameter bristles (Rovers ® VibaBrush, Rovers Medical Devices, Oss, The Netherlands), or a small soft nylon brush simi lar to a Christmas treeshaped mascara brush. Yet other approaches use plungerlike devices (Delphi device; Delphi Devices, Scherpenzeel, The Netherlands) to carry out a vaginal lavage. Women may be reluctant to use devices that look uncomfortable or appear like medical implements; to some extent even simple swabs may be resisted by some women. There are now several companies focused on delivering elegant selfcollection devices, with a look and feel that is more appealing to women (e.g., the Eva lyn ® sampler, Rovers Medical Devices). While such devices may cost more, they may be more acceptable, more readily used and returned at higher rates to the clinicians, thus promoting greater compliance with screening and saving costs in the long run.
Sensitivity & specificity of vaginal self-sampling
Overall, the reviews that compared selfcollection versus cliniciancollected samples found compa rable values for HPV prevalence [65] [66] [67] , although selfcollection may detect more lowrisk HPV types [65, 68] . The performance of the HPV test on selfcollected sample, in terms of clinical sen sitivity and specificity for CIN2+ in the screen ing setting, is not as good as HPV testing on cliniciantaken cervical specimens. Of the ten studies comparing selfcollected samples versus cliniciancollected samples reported by Snijders et al., nine found the cliniciancollected sample to be more sensitive and one found it to be as sensitive [13] . In most studies, the sensitivity or specificity of selfcollected samples is quite variable, showing values between 60 and 90% [13] . Best results, in terms of clinical sensitivity and specificity, depend on the combination of the sampler, transport conditions (medium and conduits) and the assay. Clinical validation of a combination, rather than just its individual components, should be required before it is used in routine practice [13] .
It is fairly clear that HPV testing on selfcol lected samples is as sensitive, and sometimes more sensitive, than developedcountry cytologybased screening of cervical specimens; however, cytol ogy is the more specific test [13] . By contrast, in resource constrained regions where routine cytol ogy is often quite poor, HPV testing on self collected samples is usually more sensitive than cytologybased screening. A large randomized clinical trial in Mexico [69] and several smaller observational studies in China [70] have shown that HPV testing of selfcollected specimens is a much more sensitive approach than local routine cytology screening and may address issues related to the lack of access of poor women to screening. The study by LazcanoPonce et al. in Morelos State (Mexico) randomized 25,061 women living in 540 poor communities to either routine clinic based cytology or selfcollection in their homes followed by HPV testing. Women who showed positive results on either test were referred to rou tine colposcopy and biopsy of any abnormal areas of the cervix [69] . Among the 11,054 participants of the cytology arm, there were 38 CIN2+ discov ered, of which eight were invasive cancers, while among the 9292 participants in the HPV arm there were 108 CIN2+ detected, of which 28 were cancers; overall 3.4times (95% CI: 2.4-4.9) more highgrade CIN were detected by HPV testing on selfcollected samples than by routine cytology. A report from China presents a pooled ana lysis of the diagnostic accuracy of selfcollec tion in five smalltomedium populationbased studies of mostly poor, rural women [70] . The reference standard for these studies was colpos copy (with biopsy when appropriate) on women who tested positive on any of the screening tests, including liquidbased cytology, visual inspection by acetic acid, selfcollection and physicianbased cervical HPV testing (using the same HPV assay as in Mexico). Of 13,004 women in the pooled ana lysis, 507 were diagnosed with CIN2+. Self collection with HPV testing had a sensitivity of 86.2% and a specificity of 80.7%, compared with a sensitivity of 97% and a specificity of 82.7% for physicianbased HPV testing. Liquidbased cytology was significantly less sensitive than either HPV test.
Cervical screening using vaginal self-sampling for HPV testing
Conventional cervical screening has never been successfully transferred to developing or lowincome countries because of the need for infrastructure and the associated costs. Un surprisingly, 85% of the global burden of cervical cancer arises from these areas [101] . How ever, selfcollection is comparatively resource efficient and has the potential to provide effec tive, widely available screening to these largely unscreened populations [69, 71, 72] .
Studies mainly in The Netherlands and Scandinavia have shown a way to implement selfcollection in developed countries that is complementary to current screening systems, regardless of whether the primary screening is based on cytology or HPV testing. The main problem in these countries is a lack of adher ence to screening guidelines. Several studies have shown that offering selfcollection to noncom pliant women was superior to a recall invitation for cytology, in attracting them to participate again in the screening program [13, 58] . Nine studies reporting response rates to selfsampling amongst nonattendees showed that between 8 and 39% of nonattendees of the cervical screen ing program provided selfcollection samples to the laboratory [73] [74] [75] [76] [77] [78] [79] [80] [81] . GiorgiRossi et al. found a substantial decrease in participation among Ital ian women when selfsampling was available as an optin versus providing selfcollection devices directly to the nonattendees (8.7 vs 19.6%) [73] . An interesting study of selfcollection in The Netherlands used the national postal service to deliver and return the devices [77] . The research team studied 26,409 noncompliant women of whom 26,145 were offered selfcollection, while a control group of 264 women were offered a reinvitation to cytology. They found a 30.8% return of the selfcollection devices versus 6.5% of the control group who attended cytology screening. Subsequently 89% of the HPVpos itive women took a triage cytology test, with 95.8% of those with abnormal cytology going to colposcopy. The rate of CIN2+ and invasive cancer discovered on colposcopy in the self collection group was 1.5 and 0.1%, respectively, rates that are similar to those seen in the develop ing world. The next challenge for selfcollection in countries with an established screening pro gram will be to see whether the increased cover age observed in research settings will translate into population screening. Achieving high rates of women attending triage following an HPV positive selfsampling test (reflex cytology is not possible from the selfsample), presents a particu lar challenge. This is why a molecular test (such as DNA methylation or geno typing) from the selfcollected sample is attractive because it can be carried out without requesting another sample or an examination. Currently the only commer cially available molecular triage is genotyping for HPV16 and perhaps HPV18, although the latter has questionable specificity; however, in the future methylation may provide a suitable triage assay for vaginal selfcollected samples.
Overall, the studies support the use of self collection to improve cervical cancer prevention in noncompliant and poor women worldwide. It appears that the next logical step is largescale pilot implementation of HPV testing on self collected samples in developed countries, as well as in resourceconstrained regions and poor countries that have sufficient economic capacity and provider skills, with appropriate infrastruc ture. Prior to implementation, there should be a thoughtful ana lysis of the program including: the screening groups and means of contact; the primary testing and triage approach; render ing of accurate final diagnoses; and treatment, followup and documentation.
Conclusion
HPV testing is seen to be the preferred approach to primary cervical screening in both high and lowresource settings [82] . Testing for HPV in vaginal selfcollected samples offers a relatively cheap and effective way of improving cervical screening coverage in many settings. Currently the best wellvalidated option for triage of HPV positive women is cytology, but that requires a cliniciancollected sample from the cervix. Geno typing for HPV16 and some other HPV types, or alternatively p16 alone or in combination with Ki-67, are also currently under evaluation as pos sible triage options for hrHPVpositive women. In the future, DNA methylation may provide a suitable triage assay for vaginal selfcollected samples. Even with affordable HPV testing, middle and lowincome countries will have to overcome the infrastructure challenges needed to ensure good followup, triage and treatment of HPVpositive women.
Future perspective
HPV cotesting has become the predominant method of screening in the USA. Eventually, HPV testing is likely to become the primary screen in the USA, with cytology used as the tri age test for hrHPVpositive women. In the next 5-10 years, HPV testing will be introduced as the primary screening test in organized screen ing programs in many countries in Europe. HPV screening in Asia and Latin America is also taking hold; there will be a diversity of tests and approaches and, in general, adoption will be quite slow and regionspecific. Triage of HPVpositive women, using various combina tions of genotyping, immunochemistry and molecular markers, will begin to be introduced as part of some populationbased screening
Executive summary
Human papillomavirus testing • High-risk human papillomavirus (hrHPV) infection is needed for cervical cancer to develop, and since hrHPV DNA is still present during the development of cancer, looking for hrHPV DNA should be a good approach to identifying women with high-grade cervical intraepithelial neoplasia. • The advantages of hrHPV testing over cytology (currently the most widely used screening method) are that HPV-negative women are extremely unlikely to develop cervical cancer over the next 5-10 years and infrequent screening would be safe. Additionally, HPV testing does not depend on the collection of samples with good morphology. • Screening for cervical cancer using HPV testing is more sensitive than screening using cytology, but considerably less specific. A greater proportion of women will test HPV-positive on a single screen compared with the proportion found to have abnormal cytology. Therefore, a good way of managing HPV-positive individuals is essential.
Management of women positive for HPV
• A positive HPV test in primary screening should only trigger a triage test, not automatic referral to colposcopy. The most widely studied triage test in this situation is cytology. Triage with cytology can be carried out on the same sample as the HPV test without the need for women to attend the clinic again. • HPV-positive women with normal cytology do not need to be retested at a short interval, but neither should they be rescreened only every 3 or 5 years. A repeat test after an interval of 12-24 months seems reasonable. • Genotyping for HPV16 and HPV18 has been proposed as a good alternative for women who test HPV-positive and cytology-negative because the risk of cervical intraepithelial neoplasia 3+ is genotype-dependent and HPV16 or HPV18 are found in over 70% of cervical cancer. However, being HPV-positive, but HPV16-and 18-negative, confers an increased risk of cervical disease and these women cannot be returned to routine screening. • One particularly promising triage test is the immunocytochemical detection of overexpression of the p16INK4a tumor suppressor gene as a surrogate marker for the transforming activity of hrHPV oncoproteins, which are essential for the initiation and maintenance of the neoplastic process. Currently the potential of this test is limited by the lack of standardized reporting and a need for substantial expert interpretation. • DNA methylation of a panel of both human and HPV gene markers to be used as triage tests is an exciting area of current research.
Vaginal self-collection for HPV-testing
• Testing for HPV in vaginal self-collected samples offers a relatively cheap and effective way of improving cervical screening coverage in many settings. • The performance of the HPV test on self-collected samples, in terms of clinical sensitivity and specificity for cervical intraepithelial neoplasia 2 and above in the screening setting, is not as good as HPV testing on clinician-taken cervical specimens; in most studies the sensitivity or specificity are quite variable, showing values between 60 and 90%. However, it is fairly clear that HPV testing on selfcollected samples is as sensitive, and sometimes more sensitive, than developed-country cytology-based screening of cervical specimens, although cytology is the more specific test.
Conclusion
• HPV testing is the preferred approach to primary cervical screening in both high-and low-resource settings.
• The best well-validated option for triage of HPV-positive women is cytology. Genotyping for HPV16 and some other HPV types, or alternatively p16 alone or in combination with Ki-67, are also currently under evaluation as possible triage options for hrHPV-positive women. • Testing for HPV in vaginal self-collected samples offers a relatively cheap and effective way of improving cervical screening coverage in many settings. • In the future, DNA methylation may provide a suitable triage assay for vaginal self-collected samples.
programs. Vaginal selfcollection will be used to boost coverage wherever HPV testing is used.
The impact of HPV vaccination on women of HPV screening age (those over 30 years of age) is still 5-10 years away and more data on the popu lationbased efficacy of the vaccine for preventing cervical cancer will be needed before recommen dations on altering current screening algorithms can be made. Rational algorithms will distinguish women known to have been vaccinated (three doses) while under the age of 15 years from those not known to have been vaccinated or known to have received less than three doses of the vac cine against HPV16 and HPV18. Nevertheless, a combination of HPV vaccination and HPV testing will be the cornerstone of c ervical cancer control globally.
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